Welcome to Cytosystems Ltd
Cytosystems has developed a unique urine-based diagnostic solution for the detection of cancer of the bladder and the prostate. The company, established in 2006, with its headquarters in Aberdeen, Scotland, has secured exclusive worldwide license rights from Cancer Research Technology (CRT) to deploy MCM protein antibodies using liquid based cytology (LBC) and histology in the screening, diagnosis and monitoring of bladder and prostate cancers. The core MCM technology is used to detect cell turnover including malignancy and was developed at Cambridge University.
Cytosystems is continuing to develop an integrated diagnostic package for specific cancers – The Cytosystems Solution – based on MCM antibody technology which includes an optional IP-protected, engineered urine collection system and an automated digitized slide reading device.